<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cellectar Biosciences Inc — News on 6ix</title>
<link>https://6ix.com/company/cellectar-biosciences-inc</link>
<description>Latest news and press releases for Cellectar Biosciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 14 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cellectar-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835567f78dffbe2df0e9c48.webp</url>
<title>Cellectar Biosciences Inc</title>
<link>https://6ix.com/company/cellectar-biosciences-inc</link>
</image>
<item>
<title>Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-enrolls-first-patient-in-clr-125-auger-emitting-radioconjugate-phase-1b-clinical-trial-targeting-refractory-triple-negative-breast-cancer-tnbc</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-enrolls-first-patient-in-clr-125-auger-emitting-radioconjugate-phase-1b-clinical-trial-targeting-refractory-triple-negative-breast-cancer-tnbc</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of CLR 125 in refractory TNBC, to determine recommended</description>
</item>
<item>
<title>Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-reports-financial-results-for-year-ended-2025-and-provides-corporate-updates</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-reports-financial-results-for-year-ended-2025-and-provides-corporate-updates</guid>
<pubDate>Wed, 04 Mar 2026 12:15:00 GMT</pubDate>
<description>On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia Initiated Phase 1b dose finding study for CLR 125 in Triple Negative Breast Cancer with early data expected by mid-year 2026 Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-</description>
</item>
<item>
<title>Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-to-report-full-year-financial-results-and-host-a-conference-call-on-wednesday-march-4-2026</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-to-report-full-year-financial-results-and-host-a-conference-call-on-wednesday-march-4-2026</guid>
<pubDate>Wed, 25 Feb 2026 13:05:00 GMT</pubDate>
<description>FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the full year ended December 31, 2025, and provide a corporate update on March 4, 2026, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Wednesday, March 4, 2026Time:8:30 am Eastern TimeToll</description>
</item>
<item>
<title>Cellectar Biosciences Expands Global Intellectual Property Estate</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-expands-global-intellectual-130500745</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-expands-global-intellectual-130500745</guid>
<pubDate>Tue, 17 Feb 2026 13:05:00 GMT</pubDate>
<description>Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Provides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing Approval with the European Medicines Agency (EMA) for Iopofosine I 131 as a Treatment for Waldenström Macroglobulinemia FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and develo</description>
</item>
<item>
<title>Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-highlight-strategic-initiatives-130500479</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-highlight-strategic-initiatives-130500479</guid>
<pubDate>Fri, 09 Jan 2026 13:05:00 GMT</pubDate>
<description>Following Guidance from the European Medicines Agency’s (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom’s Macroglobulinemia (WM), Expects to Submit for Conditional Marketing Approval in Europe in 3Q 2026 Plans to Present Final Results and Subset Analysis of WM Patients from the Phase 2 CLOVER WaM Clinical Study of Iopofosine I 131 Anticipates Dosing of First Patients in Phase 1b Study of CLR 125 for the Treatment of Triple Negative Breast</description>
</item>
<item>
<title>Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-announces-strategic-supply-130500718</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-announces-strategic-supply-130500718</guid>
<pubDate>Tue, 16 Dec 2025 13:05:00 GMT</pubDate>
<description>Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid TumorsFLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a multi-year supply agreement with Ionetix Corporation, a leading cyclotron technology innovator and full-service radioisotope manufacturer,</description>
</item>
<item>
<title>Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-reports-third-quarter-122000570</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-reports-third-quarter-122000570</guid>
<pubDate>Thu, 13 Nov 2025 12:20:00 GMT</pubDate>
<description>Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom’s Macroglobulinemia in 2026 Following Advice and Guidance from Scientific Advice Working Party (SAWP) Initiated Phase 1b Study of CLR 125 for TNBC Received Rare Pediatric Drug Designation for Iopofosine I 131 in Inoperable Relapsed/Refractory Pediatric High-Grade Glioma (r/r pHGG) Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., Nov.</description>
</item>
<item>
<title>Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-report-third-quarter-130500469</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-report-third-quarter-130500469</guid>
<pubDate>Thu, 06 Nov 2025 13:05:00 GMT</pubDate>
<description>FLORHAM PARK, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company will report financial results for the third quarter ended September 30, 2025, and provide a corporate update on November 13, 2025, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Thursday, November 13, 2025Time:8:30 am Easte</description>
</item>
<item>
<title>Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-receives-rare-pediatric-123000510</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-receives-rare-pediatric-123000510</guid>
<pubDate>Mon, 27 Oct 2025 12:30:00 GMT</pubDate>
<description>CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival and Overall SurvivalFLORHAM PARK, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the U.S. Food and Drug Administration (FDA) has granted rare pediatric drug d</description>
</item>
<item>
<title>Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-presented-promising-preclinical-123000985</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-presented-promising-preclinical-123000985</guid>
<pubDate>Tue, 14 Oct 2025 12:30:00 GMT</pubDate>
<description>CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft ModelsFLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer of Cellectar, presented positive preclinical data in a</description>
</item>
<item>
<title>Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-inc-enters-agreements-123000855</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-inc-enters-agreements-123000855</guid>
<pubDate>Tue, 07 Oct 2025 12:30:00 GMT</pubDate>
<description>FLORHAM PARK, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (“Cellectar” or the “company”), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment of cancer, today announced an agreement between the company and several institutional investors to exercise certain existing warrants (the “Existing Warrants”) for gross proceeds to the company of approximately $5.8 million prior to deducting placement agent fees and e</description>
</item>
<item>
<title>Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-announces-european-medicines-110000771</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-announces-european-medicines-110000771</guid>
<pubDate>Mon, 06 Oct 2025 11:00:00 GMT</pubDate>
<description>Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM Expected in Early 2026 Potential 2027 European Approval and Commercial Launch of Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM FLORHAM PARK, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discove</description>
</item>
<item>
<title>Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-presented-compelling-data-123000643</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-presented-compelling-data-123000643</guid>
<pubDate>Tue, 30 Sep 2025 12:30:00 GMT</pubDate>
<description>CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression-Free Survival and Overall SurvivalFLORHAM PARK, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer of Cellectar, delivered an oral</description>
</item>
<item>
<title>Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-evestia-clinical-announce-partnership-123000201</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-evestia-clinical-announce-partnership-123000201</guid>
<pubDate>Wed, 24 Sep 2025 12:30:00 GMT</pubDate>
<description>Intends to Initiate Phase 1b Clinical Trial in TNBC at Mayo Clinic in Fourth Quarter 2025FLORHAM PARK, N.J. and LONDON and CHARLOTTESVILLE, Va., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (“Cellectar”) (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Evestia Clinical (“Evestia”), a leading independent global specialist Contract Research Organization (CRO), have entered into an ag</description>
</item>
<item>
<title>Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-itm-enter-supply-120500349</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-itm-enter-supply-120500349</guid>
<pubDate>Thu, 11 Sep 2025 12:05:00 GMT</pubDate>
<description>Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid TumorsFLORHAM PARK, N.J. and GARCHING, Germany and MUNICH, Germany, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB, “Cellectar”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced a supp</description>
</item>
<item>
<title>Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-participate-oppenheimer-3rd-120500673</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-participate-oppenheimer-3rd-120500673</guid>
<pubDate>Tue, 09 Sep 2025 12:05:00 GMT</pubDate>
<description>Highlighting Continued Progress with EMA Regarding a Potential Conditional Marketing Authorization Submission for Iopofosine I 131 to Treat Waldenstrom Macroglobulinemia (WM) in the EU; Decision on Track for Late 3Q25/Early 4Q25 Intention to Pursue an Accelerated Approval with the U.S. Food and Drug Administration for Iopofosine I 131 as a Treatment for WM Advancing Auger-Emitting Radiopharmaceutical Product Candidate into Phase 1b Clinical Trial for the Treatment of Triple-Negative Breast Cance</description>
</item>
<item>
<title>Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-participate-multiple-upcoming-124500374</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-participate-multiple-upcoming-124500374</guid>
<pubDate>Fri, 05 Sep 2025 12:45:00 GMT</pubDate>
<description>FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer at Cellectar Biosciences, will participate in panel discussions and present at multiple medical meetings and industry conferences in September. Details are as follows: ADC and Novel Conjugates Partnering and Inves</description>
</item>
<item>
<title>Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-present-data-poster-120500501</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-present-data-poster-120500501</guid>
<pubDate>Wed, 03 Sep 2025 12:05:00 GMT</pubDate>
<description>FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts. The poster presentation will highlight</description>
</item>
<item>
<title>Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-present-data-oral-120500573</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-present-data-oral-120500573</guid>
<pubDate>Wed, 27 Aug 2025 12:05:00 GMT</pubDate>
<description>Presenting Data from CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma (r/r pHGG) PatientsFLORHAM PARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for oral presentation followed by a 55-minute panel discussion with other expe</description>
</item>
<item>
<title>Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-reports-second-quarter-111900234</link>
<guid isPermaLink="true">https://6ix.com/company/cellectar-biosciences-inc/news/cellectar-biosciences-reports-second-quarter-111900234</guid>
<pubDate>Thu, 14 Aug 2025 11:19:00 GMT</pubDate>
<description>Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway Continue to Work with the EMA Toward a Potential Submission of Iopofosine I 131 for Conditional Approval in the EU; Decision expected late 3Q early 4Q 2025 On track to advance CLR 125 into Phase 1 TNBC trial 4Q 2025 Company to Hold Webcast and Conference Call at</description>
</item>
</channel>
</rss>